DOCSLIB.ORG

Characterization of Species-Related Differences in the Pharmacology Of

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Characterization of Species-Related Differences in the Pharmacology Of Characterization of species-related differences in the pharmacology of tachykinin NK receptors 1, 2 and 3 Agnes Leffler, Ingela Ahlstedt, Susanna Engberg, Arne Svensson, Martin Billger, Lisa Öberg, Magnus Bjursell, Erik Lindström, Bengt von Mentzer To cite this version: Agnes Leffler, Ingela Ahlstedt, Susanna Engberg, Arne Svensson, Martin Billger, et al.. Characteri- zation of species-related differences in the pharmacology of tachykinin NK receptors 1, 2 and3.Bio- chemical Pharmacology, Elsevier, 2009, 77 (9), pp.1522. 10.1016/j.bcp.2009.01.020. hal-00493489 HAL Id: hal-00493489 https://hal.archives-ouvertes.fr/hal-00493489 Submitted on 19 Jun 2010 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Accepted Manuscript Title: Characterization of species-related differences in the pharmacology of tachykinin NK receptors 1, 2 and 3 Authors: Agnes Leffler, Ingela Ahlstedt, Susanna Engberg, Arne Svensson, Martin Billger, Lisa Oberg,¨ Magnus Bjursell, Erik Lindstrom,¨ Bengt von Mentzer PII: S0006-2952(09)00055-0 DOI: doi:10.1016/j.bcp.2009.01.020 Reference: BCP 10080 To appear in: BCP Received date: 19-11-2008 Revised date: 27-1-2009 Accepted date: 30-1-2009 Please cite this article as: Leffler A, Ahlstedt I, Engberg S, Svensson A, Billger M, Oberg¨ L, Bjursell M, Lindstrom¨ E, von Mentzer B, Characterization of species-related differences in the pharmacology of tachykinin NK receptors 1, 2 and 3, Biochemical Pharmacology (2008), doi:10.1016/j.bcp.2009.01.020 This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. * Manuscript von Mentzer et al 1 Short title: NK receptor pharmacology 1 2 3 4 5 6 Characterization of species-related differences in the pharmacology 7 8 of tachykinin NK receptors 1, 2 and 3. 9 10 11 12 Agnes Lefflera, Ingela Ahlstedta, Susanna Engberga, Arne Svenssona, Martin Billgerb, 13 14 a 1 2 * 15 Lisa Öberg , Magnus Bjursell , Erik Lindström and Bengt von Mentzer . 16 17 AstraZeneca R&D, Mölndal, Sweden. 18 19 20 21 22 *Corresponding author: Dr. Bengt von Mentzer, Pharmnovo AB, Medicinaregatan 23 24 8A, S-413 46 Göteborg, Sweden. Tel.: +46 31 7411816, Fax. +46 31 7411701, E- 25 26 27 mail: [email protected] 28 29 1Current affiliation: Royal Institute of technology, Albanova University Centre, SE- 30 31 32 10691 Stockholm, Sweden 33 34 2Current affiliation: Medivir AB, PO Box 1086, S-141 22, Huddinge, Sweden 35 36 aDepartment of Bioscience 37 38 b 39 Safety Assessment 40 41 42 43 44 Key words: Aprepitant; Saredutant; Talnetant; NK receptors; Species difference; NK- 45 46 receptor function; Chemistry; NK-receptor sequences 47 48 Accepted Manuscript 49 50 51 Abbreviations: NKR, tachykinin NK receptor; SP, Substance P; NKA, Neurokinin A; 52 53 NKB, Neurokinin B; AA, amino acids; FLIPR, Fluorometric Imaging Plate Reader; 54 55 56 TM. trans membrane 57 58 59 60 61 62 63 1 64 Page 1 of 35 65 von Mentzer et al 2 1 2 Abstract 3 4 5 Tachykinin NK receptors (NKR) differ to a large degree among species with respect 6 7 to their affinities for small molecule antagonists. The aims of the present study were 8 9 10 to clone NKRs from gerbil (NK2R and NK3R) and dog (NK1R, NK2R, NK3R) in 11 12 which the sequence was previously unknown and to investigate the potency of several 13 14 15 NKR antagonists at all known human, dog, gerbil and rat NKRs. 16 17 The NKR protein coding sequences were cloned and expressed in CHO cells. The 18 19 inhibitory concentrations of selective and non-selective NKR antagonists were 20 21 2+ 22 determined by inhibition of agonist-induced mobilization of intracellular Ca . 23 24 Receptor homology models were constructed based on the rhodopsin crystal structure 25 26 27 to investigate and identify the antagonist binding sites and interaction points in the 28 29 trans membrane (TM) regions of the NKRs. 30 31 32 Data collected using the cloned dog NK1R confirmed that the dog NK1R displays 33 34 similar pharmacology as the human and the gerbil NK1R, but differs greatly from the 35 36 mouse and the rat NK R. Despite species-related AA differences located close to the 37 1 38 39 antagonist binding pocket of the NK2R, they did not affect the potency of the 40 41 antagonists ZD6021 and saredutant. Two AA differences located close to the 42 43 44 antagonist binding site of NK3R likely influence the NK3R antagonist potency, 45 46 explaining the 3-10-fold decrease in potency observed for the rat NK3R. For the first 47 48 time, detailedAccepted pharmacological experiments in vitroManuscript with cloned NKRs demonstrate 49 50 51 that not only human, but also dog and gerbil NKR displays similar antagonist 52 53 pharmacology while rat diverges significantly with respect to NK R and NK R. 54 1 3 55 56 57 58 59 60 61 62 63 2 64 Page 2 of 35 65 von Mentzer et al 3 1. Introduction 1 2 3 4 5 Several small molecule antagonists selective for tachykinin NK1R, NK2R and NK3R 6 7 are in clinical development and the selective NK1R antagonist aprepitant is approved 8 9 10 for treatment of emesis in response to cytostatic treatment in cancer patients [1]. 11 12 During the development of selective NK1R antagonists, Beresford et al. discovered 13 14 15 large discrepancies in the affinity for NK1R from different species [2]. This led to the 16 17 NK1R family being grouped into two sub-families based on the orthologous receptor’s 18 19 affinity to small molecule antagonists. The first sub-family consists of the human, 20 21 22 guinea pig, rabbit, dog, gerbil and ferret NK1R, and the second sub-family of the rat 23 24 and mouse homologues [2,3,4,5] Thus, several disease-related animal models in 25 26 27 species other than rat or mouse have been developed for evaluation of NK1R 28 29 antagonists [6,7,8,9,10] Amino acid residues in the NK1R responsible for species- 30 31 32 dependent differences in antagonist pharmacology have been studied in detail, 33 34 especially human Glu97, Val116 and Ser290 [5,11,12,13,14]However, although the 35 36 dog appears to be an appropriate species in detecting anti-emetic effects with selective 37 38 39 NK1R antagonists intended for clinical use [15], the pharmacology of the dog NK1R 40 41 at the molecular level, and its homology to the human NK1R, remain unknown to our 42 43 44 knowledge. 45 46 Consistent species-related differences in the pharmacology of NK2R have not been 47 48 reported either,Accepted although recent publications demonstrated Manuscript that the selective NK2R 49 50 51 antagonist MEN15596 and analogues MEN14268 and MEN13918 had a marked 52 53 species selectivity for inhibiting NK R-mediated effects in human, guinea pig and pig 54 2 55 56 urinary bladder, while being 1,000-fold less potent at the rat and mouse NK2R 57 58 expressed in urinary bladder [16,17] . By contrast, species-dependent differences were 59 60 61 62 63 3 64 Page 3 of 35 65 von Mentzer et al 4 not observed with MEN11420 (nepadutant) [18] or saredutant [19] Detailed site- 1 2 directed mutagenesis studies suggested that the Ile202 residue, located in the upper 3 4 5 part of TM5 in the human NK2R was, at least in part, responsible for these differences 6 7 [16] Still, the homology between the human NK2R and that of species commonly used 8 9 10 in tachykinin receptor pharmacology studies, such as dog and gerbil, has not been 11 12 reported. 13 14 15 Furthermore, species-related differences in functional response profiles between 16 17 human and mouse/rat have been reported for selective tachykinin NK3R antagonists. 18 19 Compounds from different structural classes have 5-10-fold lower potency and 10-50- 20 21 22 fold lower affinity for rodent NK3R compared to human counterparts [20,21] Site- 23 24 directed mutagenesis studies indicate that two amino acids in the second trans 25 26 27 membrane domain of the human NK3R (Met134 and Ala146) were responsible for 28 29 these species differences [20,22] However, as is the case for NK2R, the identity of 30 31 32 NK3R from dog and gerbil remain unknown. 33 34 Thus, there are clearly gaps in our knowledge with respect to which species most 35 36 likely will predict clinical efficacy and selectivity for NK R, NK R or NK R 37 1 2 3 38 39 antagonists. Furthermore, the lack of antagonist affinity data will complicate species 40 41 selection for toxicological studies intended to detect adverse effects upon blocking of 42 43 44 receptor signalling. In the current study, we have cloned and sequenced the dog 45 46 NK1R, NK2R and NK3R and the gerbil NK2R.
Load more

Recommended publications
  • Drug Development for the Irritable Bowel Syndrome: Current Challenges and Future Perspectives
    REVIEW ARTICLE published: 01 February 2013 doi: 10.3389/fphar.2013.00007 Drug development for the irritable bowel syndrome: current challenges and future perspectives Fabrizio De Ponti* Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy Edited by: Medications are frequently used for the treatment of patients with the irritable bowel syn- Angelo A. Izzo, University of Naples drome (IBS), although their actual benefit is often debated. In fact, the recent progress in Federico II, Italy our understanding of the pathophysiology of IBS, accompanied by a large number of preclin- Reviewed by: Elisabetta Barocelli, University of ical and clinical studies of new drugs, has not been matched by a significant improvement Parma, Italy of the armamentarium of medications available to treat IBS. The aim of this review is to Raffaele Capasso, University of outline the current challenges in drug development for IBS, taking advantage of what we Naples Federico II, Italy have learnt through the Rome process (Rome I, Rome II, and Rome III). The key questions *Correspondence: that will be addressed are: (a) do we still believe in the “magic bullet,” i.e., a very selective Fabrizio De Ponti, Pharmacology Unit, Department of Medical and Surgical drug displaying a single receptor mechanism capable of controlling IBS symptoms? (b) IBS Sciences, University of Bologna, Via is a “functional disorder” where complex neuroimmune and brain-gut interactions occur Irnerio, 48, 40126 Bologna, Italy. and minimal inflammation is often documented:
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2012/0190743 A1 Bain Et Al
    US 2012O190743A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0190743 A1 Bain et al. (43) Pub. Date: Jul. 26, 2012 (54) COMPOUNDS FOR TREATING DISORDERS Publication Classification OR DISEASES ASSOCATED WITH (51) Int. Cl NEUROKININ 2 RECEPTORACTIVITY A6II 3L/23 (2006.01) (75) Inventors: Jerald Bain, Toronto (CA); Joel CD7C 69/30 (2006.01) Sadavoy, Toronto (CA); Hao Chen, 39t. ii; C Columbia, MD (US); Xiaoyu Shen, ( .01) Columbia, MD (US) A6IPI/00 (2006.01) s A6IP 29/00 (2006.01) (73) Assignee: UNITED PARAGON A6IP II/00 (2006.01) ASSOCIATES INC., Guelph, ON A6IPI3/10 (2006.01) (CA) A6IP 5/00 (2006.01) A6IP 25/00 (2006.01) (21) Appl. No.: 13/394,067 A6IP 25/30 (2006.01) A6IP5/00 (2006.01) (22) PCT Filed: Sep. 7, 2010 A6IP3/00 (2006.01) CI2N 5/071 (2010.01) (86). PCT No.: PCT/US 10/48OO6 CD7C 69/33 (2006.01) S371 (c)(1) (52) U.S. Cl. .......................... 514/552; 554/227; 435/375 (2), (4) Date: Apr. 12, 2012 (57) ABSTRACT Related U.S. Application Data Compounds, pharmaceutical compositions and methods of (60) Provisional application No. 61/240,014, filed on Sep. treating a disorder or disease associated with neurokinin 2 4, 2009. (NK) receptor activity. Patent Application Publication Jul. 26, 2012 Sheet 1 of 12 US 2012/O190743 A1 LU 1750 15OO 1250 OOO 750 500 250 O O 20 3O 40 min SampleName: EM2OO617 Patent Application Publication Jul. 26, 2012 Sheet 2 of 12 US 2012/O190743 A1 kixto CFUgan <tro CFUgan FIG.2 Patent Application Publication Jul.
    [Show full text]
  • Nitrate Prodrugs Able to Release Nitric Oxide in a Controlled and Selective
    Europäisches Patentamt *EP001336602A1* (19) European Patent Office Office européen des brevets (11) EP 1 336 602 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.7: C07C 205/00, A61K 31/00 20.08.2003 Bulletin 2003/34 (21) Application number: 02425075.5 (22) Date of filing: 13.02.2002 (84) Designated Contracting States: (71) Applicant: Scaramuzzino, Giovanni AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU 20052 Monza (Milano) (IT) MC NL PT SE TR Designated Extension States: (72) Inventor: Scaramuzzino, Giovanni AL LT LV MK RO SI 20052 Monza (Milano) (IT) (54) Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases (57) New pharmaceutical compounds of general effects and for this reason they are useful for the prep- formula (I): F-(X)q where q is an integer from 1 to 5, pref- aration of medicines for prevention and treatment of in- erably 1; -F is chosen among drugs described in the text, flammatory, ischemic, degenerative and proliferative -X is chosen among 4 groups -M, -T, -V and -Y as de- diseases of musculoskeletal, tegumental, respiratory, scribed in the text. gastrointestinal, genito-urinary and central nervous sys- The compounds of general formula (I) are nitrate tems. prodrugs which can release nitric oxide in vivo in a con- trolled and selective way and without hypotensive side EP 1 336 602 A1 Printed by Jouve, 75001 PARIS (FR) EP 1 336 602 A1 Description [0001] The present invention relates to new nitrate prodrugs which can release nitric oxide in vivo in a controlled and selective way and without the side effects typical of nitrate vasodilators drugs.
    [Show full text]
  • United States Patent (10) Patent No.: US 8,969,514 B2 Shailubhai (45) Date of Patent: Mar
    USOO896.9514B2 (12) United States Patent (10) Patent No.: US 8,969,514 B2 Shailubhai (45) Date of Patent: Mar. 3, 2015 (54) AGONISTS OF GUANYLATECYCLASE 5,879.656 A 3, 1999 Waldman USEFUL FOR THE TREATMENT OF 36; A 6. 3: Watts tal HYPERCHOLESTEROLEMIA, 6,060,037- W - A 5, 2000 Waldmlegand et al. ATHEROSCLEROSIS, CORONARY HEART 6,235,782 B1 5/2001 NEW et al. DISEASE, GALLSTONE, OBESITY AND 7,041,786 B2 * 5/2006 Shailubhai et al. ........... 530.317 OTHER CARDOVASCULAR DISEASES 2002fOO78683 A1 6/2002 Katayama et al. 2002/O12817.6 A1 9/2002 Forssmann et al. (75) Inventor: Kunwar Shailubhai, Audubon, PA (US) 2003,2002/0143015 OO73628 A1 10/20024, 2003 ShaubhaiFryburg et al. 2005, OO16244 A1 1/2005 H 11 (73) Assignee: Synergy Pharmaceuticals, Inc., New 2005, OO32684 A1 2/2005 Syer York, NY (US) 2005/0267.197 A1 12/2005 Berlin 2006, OO86653 A1 4, 2006 St. Germain (*) Notice: Subject to any disclaimer, the term of this 299;s: A. 299; NS et al. patent is extended or adjusted under 35 2008/0137318 A1 6/2008 Rangarajetal.O U.S.C. 154(b) by 742 days. 2008. O151257 A1 6/2008 Yasuda et al. 2012/O196797 A1 8, 2012 Currie et al. (21) Appl. No.: 12/630,654 FOREIGN PATENT DOCUMENTS (22) Filed: Dec. 3, 2009 DE 19744O27 4f1999 (65) Prior Publication Data WO WO-8805306 T 1988 WO WO99,26567 A1 6, 1999 US 2010/O152118A1 Jun. 17, 2010 WO WO-0 125266 A1 4, 2001 WO WO-02062369 A2 8, 2002 Related U.S.
    [Show full text]
  • Tachykinins and Airway Microvascular Leakage Induced by Hcl Intra-Oesophageal Instillation
    Copyright #ERS Journals Ltd 2002 Eur Respir J 2002; 20: 268–273 European Respiratory Journal DOI: 10.1183/09031936.02.00250902 ISSN 0903-1936 Printed in UK – all rights reserved Tachykinins and airway microvascular leakage induced by HCl intra-oesophageal instillation S. Daoui*,B.D9Agostino#, L. Gallelli#, X. Emonds Alt}, F. Rossi#, C. Advenier* Tachykinins and airway microvascular leakage induced by HCl intra-oesophageal *Dept of Pharmacology, University instillation. S. Daoui, B. D9Agostino, L. Gallelli, X. Emonds Alt, F. Rossi, C. Advenier. Paris V, Paris, France, #Dept of #ERS Journals Ltd 2002. Experimental Medicine, Faculty of ABSTRACT: Gastro-oesophageal reflux is a common clinical disorder associated with Medicine and Surgery, Naples, Italy, }Sanofi Synthelabo Research, Montpel- a variety of respiratory symptoms, including chronic cough and exacerbation of asthma. lier, France. In this study, the potential role of acid-induced tachykinin release was examined in guinea pigs and rabbits, by examining the effects of the tachykinin NK1 and NK3 Correspondence: C. Advenier receptors antagonists (SR 140333 and SR 142801, respectively) (1–10 mg?kg-1)on Universite´ Paris V plasma protein extravasation induced in airways by hydrochloric acid (HCl) infusion in UPRES EA220, Pharmacologie the oesophagus. 45 rue des Saints Pe`res Guinea pigs were anaesthetised with urethane, while rabbits were subject to F-75006 Paris neuroleptoanalgesia with hypnorm. Airway vascular leakage was evaluated by France Fax: 33 142863810 measuring extravasation of Evans blue dye. All animals were pretreated with atropine E-mail: [email protected] (1 mg?kg-1 i.p.), propranolol (1 mg?kg-1 i.p.), phosphoramidon (2.5 mg?kg-1 i.v.) and -1 saline or tachykinin receptor antagonists (1–10 mg?kg i.p.).
    [Show full text]
  • WO 2015/072852 Al 21 May 2015 (21.05.2015) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2015/072852 Al 21 May 2015 (21.05.2015) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 36/84 (2006.01) A61K 31/5513 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/045 (2006.01) A61P 31/22 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 31/522 (2006.01) A61K 45/06 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, PCT/NL20 14/050780 KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, (22) International Filing Date: MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, 13 November 2014 (13.1 1.2014) PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (25) Filing Language: English TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 61/903,430 13 November 2013 (13. 11.2013) US GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (71) Applicant: RJG DEVELOPMENTS B.V.
    [Show full text]
  • Modifications to the Harmonized Tariff Schedule of the United States To
    U.S. International Trade Commission COMMISSIONERS Shara L. Aranoff, Chairman Daniel R. Pearson, Vice Chairman Deanna Tanner Okun Charlotte R. Lane Irving A. Williamson Dean A. Pinkert Address all communications to Secretary to the Commission United States International Trade Commission Washington, DC 20436 U.S. International Trade Commission Washington, DC 20436 www.usitc.gov Modifications to the Harmonized Tariff Schedule of the United States to Implement the Dominican Republic- Central America-United States Free Trade Agreement With Respect to Costa Rica Publication 4038 December 2008 (This page is intentionally blank) Pursuant to the letter of request from the United States Trade Representative of December 18, 2008, set forth in the Appendix hereto, and pursuant to section 1207(a) of the Omnibus Trade and Competitiveness Act, the Commission is publishing the following modifications to the Harmonized Tariff Schedule of the United States (HTS) to implement the Dominican Republic- Central America-United States Free Trade Agreement, as approved in the Dominican Republic-Central America- United States Free Trade Agreement Implementation Act, with respect to Costa Rica. (This page is intentionally blank) Annex I Effective with respect to goods that are entered, or withdrawn from warehouse for consumption, on or after January 1, 2009, the Harmonized Tariff Schedule of the United States (HTS) is modified as provided herein, with bracketed matter included to assist in the understanding of proclaimed modifications. The following supersedes matter now in the HTS. (1). General note 4 is modified as follows: (a). by deleting from subdivision (a) the following country from the enumeration of independent beneficiary developing countries: Costa Rica (b).
    [Show full text]
  • Selective Blockade of NK2 Or NK3 Receptors Produces Anxiolytic- and Antidepressant-Like Effects in Gerbils ⁎ N
    Pharmacology, Biochemistry and Behavior 83 (2006) 533–539 www.elsevier.com/locate/pharmbiochembeh Selective blockade of NK2 or NK3 receptors produces anxiolytic- and antidepressant-like effects in gerbils ⁎ N. Salomé, J. Stemmelin, C. Cohen , G. Griebel Sanofi-Aventis, Department of Psychopharmacology, 31 av Paul Vaillant-Couturier, 92220 Bagneux, France Received 17 October 2005; received in revised form 1 March 2006; accepted 9 March 2006 Available online 19 April 2006 Abstract There is a growing interest in the potential anxiolytic- and antidepressant-like effects of compounds that target neurokinin receptors. Since the structure and the pharmacology of the human neurokinin receptor resembles that of gerbils, rather than that of mice or rats, we decided to investigate the anxiolytic- and /or antidepressant-like effects of NK1 (SSR240600), NK2 (saredutant) and NK3 (osanetant) receptor antagonists in gerbils. It was found that saredutant (3–10 mg/kg, p.o.) and osanetant (3–10 mg/kg, p.o.) produced anxiolytic-like effects in the gerbil social interaction test. These effects were similar to those obtained with the V1b receptor antagonist SSR149415 (3–10 mg/kg, p.o.), diazepam (1 mg/kg, p.o.) and buspirone (10 mg/kg, p.o.). Fluoxetine and SSR240600 were devoid of effects in this test. In the tonic immobility test in gerbils, saredutant (5–10 mg/kg, i.p.) and osanetant (5–10 mg/kg, i.p.) produced similar effects to those observed with fluoxetine (7.5–15 mg/kg, i.p.), SSR149415 (10–30 mg/kg, p.o.) and buspirone (3 mg/kg, i.p.). Diazepam and SSR240600 were inactive in this paradigm.
    [Show full text]
  • G Protein-Coupled Receptors
    S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors. British Journal of Pharmacology (2015) 172, 5744–5869 THE CONCISE GUIDE TO PHARMACOLOGY 2015/16: G protein-coupled receptors Stephen PH Alexander1, Anthony P Davenport2, Eamonn Kelly3, Neil Marrion3, John A Peters4, Helen E Benson5, Elena Faccenda5, Adam J Pawson5, Joanna L Sharman5, Christopher Southan5, Jamie A Davies5 and CGTP Collaborators 1School of Biomedical Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK, 2Clinical Pharmacology Unit, University of Cambridge, Cambridge, CB2 0QQ, UK, 3School of Physiology and Pharmacology, University of Bristol, Bristol, BS8 1TD, UK, 4Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK, 5Centre for Integrative Physiology, University of Edinburgh, Edinburgh, EH8 9XD, UK Abstract The Concise Guide to PHARMACOLOGY 2015/16 provides concise overviews of the key properties of over 1750 human drug targets with their pharmacology, plus links to an open access knowledgebase of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. The full contents can be found at http://onlinelibrary.wiley.com/doi/ 10.1111/bph.13348/full. G protein-coupled receptors are one of the eight major pharmacological targets into which the Guide is divided, with the others being: ligand-gated ion channels, voltage-gated ion channels, other ion channels, nuclear hormone receptors, catalytic receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading.
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • G Protein‐Coupled Receptors
    S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2019/20: G protein-coupled receptors. British Journal of Pharmacology (2019) 176, S21–S141 THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G protein-coupled receptors Stephen PH Alexander1 , Arthur Christopoulos2 , Anthony P Davenport3 , Eamonn Kelly4, Alistair Mathie5 , John A Peters6 , Emma L Veale5 ,JaneFArmstrong7 , Elena Faccenda7 ,SimonDHarding7 ,AdamJPawson7 , Joanna L Sharman7 , Christopher Southan7 , Jamie A Davies7 and CGTP Collaborators 1School of Life Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK 2Monash Institute of Pharmaceutical Sciences and Department of Pharmacology, Monash University, Parkville, Victoria 3052, Australia 3Clinical Pharmacology Unit, University of Cambridge, Cambridge, CB2 0QQ, UK 4School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, BS8 1TD, UK 5Medway School of Pharmacy, The Universities of Greenwich and Kent at Medway, Anson Building, Central Avenue, Chatham Maritime, Chatham, Kent, ME4 4TB, UK 6Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK 7Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, EH8 9XD, UK Abstract The Concise Guide to PHARMACOLOGY 2019/20 is the fourth in this series of biennial publications. The Concise Guide provides concise overviews of the key properties of nearly 1800 human drug targets with an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. Although the Concise Guide represents approximately 400 pages, the material presented is substantially reduced compared to information and links presented on the website.
    [Show full text]
  • Antidepressant Potential of Nitrogen-Containing Heterocyclic Moieties: an Updated Review
    Review Article Antidepressant potential of nitrogen-containing heterocyclic moieties: An updated review Nadeem Siddiqui, Andalip, Sandhya Bawa, Ruhi Ali, Obaid Afzal, M. Jawaid Akhtar, Bishmillah Azad, Rajiv Kumar Department of ABSTRACT Pharmaceutical Chemistry, Depression is currently the fourth leading cause of disease or disability worldwide. Antidepressant is Faculty of Pharmacy, Jamia Hamdard approved for the treatment of major depression (including paediatric depression), obsessive-compulsive University, Hamdard disorder (in both adult and paediatric populations), bulimia nervosa, panic disorder and premenstrual Nagar, New Delhi - dysphoric disorder. Antidepressant is a psychiatric medication used to alleviate mood disorders, such as 110 062, India major depression and dysthymia and anxiety disorders such as social anxiety disorder. Many drugs produce an antidepressant effect, but restrictions on their use have caused controversy and off-label prescription a Address for correspondence: risk, despite claims of superior efficacy. Our current understanding of its pathogenesis is limited and existing Dr. Sandhya Bawa, E-mail: sandhyabawa761@ treatments are inadequate, providing relief to only a subset of people suffering from depression. Reviews of yahoo.com literature suggest that heterocyclic moieties and their derivatives has proven success in treating depression. Received : 08-02-11 Review completed : 15-02-11 Accepted : 17-02-11 KEY WORDS: Antidepressant, depression, heterocyclic epression is a chronic, recurring and potentially life- monoamine oxidase inhibitors (MAOIs, e.g. Nardil®) tricyclic D threatening illness that affects up to 20% of the population antidepressants (TCAs, e.g. Elavil). They increases the synaptic across the globe.[1] The etiology of the disease is suboptimal concentration of either two (5-HT and NE) or all three (5-HT, concentrations of the monoamine neurotransmitters serotonin NE and dopamine (DA)) neurotransmitters.
    [Show full text]